155 currently employed with an additional 255 jobs created by end of 2012? 160% increase in the workforce? Wow! Can only imagine this means that the staff will be needed for increased production capacity.
Re the rest of it, ageing tests etc, still no word. That aside I'd also imagine that there will be two parts to each and every new deal signed with any additional pharma wanting access to the Unifill.
First an Exclusive License Agreement for the Therapeutic Drug Class in question, with appropriate up-front exclusive license fee; secondly, a Supply Agreement stipulating price aqnd quantities.
This is the model employed with Sanofi and IMO there will be no deviation for additional pharma wanting in.
Only question is how much will the Exclusive License fees be? Oh yes, and when will they start to be signed up? :)
UNS Price at posting:
83.0¢ Sentiment: Buy Disclosure: Held
